

A.E. Frankel
Reference List

Articles

Alfano RW, Leppla SH, Liu S, Bugge TH, Duesbery NS, Frankel AE. Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacy. **Cell Cycle** 7[6], 745-749. 2008.

Ding Y, Boguslawski EA, Berghuis BD, Young JJ, Zhang ZF, Hardy K, Furge K, Kort E, Frankel AE, Hay RV, Resau JH, Duesbery NS. Mitogen-activated protein kinase signaling promotes growth and vascularization of fibrosarcoma. **Molecular Cancer Therapeutics** 7[3], 648-658. 2008.

Frankel AE, Liu JS, Rizzieri D, Hogge D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. **Leukemia and Lymphoma** 49[3], 543-553. 2008.

Horita H, Frankel AE, Thorburn A. Acute-myeloid-leukemia-targeted toxins kill tumor cells by cell-type-specific mechanisms and synergize with TRAIL to allow manipulation of the extent and mechanism of tumor cell death. **Leukemia** 22[3], 652-655. 2008.

Liu S, Wang H, Currie BM, Molinolo A, Leung HJ, Moayeri M, Basile JR, Alfano RW, Gutkind JS, Frankel AE, Bugge TH, Leppla SH. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. **Journal of Biological Chemistry** 283[1], 529-540. 2008.

Rouleau C, Menon K, Boutin P, Guyre C, Yoshida H, Kataoka S, Perricone M, Shankara S, Frankel AE, Duesbery NS, Woude GV, Biemann HP, Teicher BA. The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: Assessment of receptor contribution. **International Journal of Oncology** 32[4], 739-748. 2008.

Vanderlaag K, Su Y, Frankel AE, Grage H, Smith R, III, Khan S, Safe S. 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathways. **Breast Cancer Res Treat.** 109[2], 273-283. 2008.

Woo JH, Liu JS, Kang SH, Singh R, Park SK, Su Y, Ortiz J, Neville DM, Jr., Willingham MC, Frankel AE. GMP production and characterization of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1) for phase I/II clinical trials. **Protein Expression and Purification** 58[1], 1-11. 2008.

Woo JH, Bour SH, Dang T, Lee YJ, Park SK, Andreas E, Kang SH, Liu JS, Neville DM, Jr., Frankel AE. Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1). **Cancer Immunology, Immunotherapy** . 2008.

Cheng CP, Masutani S, Cheng HJ, Cross M, Zhang CX, Zhou P, Cann J, Cline JM, Little WC, Kuo SR, Frankel AE. Progressive left ventricle, myocyte dysfunction, and heart failure in the lethality of anthrax toxin in conscious dogs. **Circulation** 116[16], 758. 2007.

Depeille P, Young JJ, Boguslawski EA, Berghuis BD, Kort EJ, Resau JH, Frankel AE, Duesbery NS. Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptor. **Clin.Cancer Res** 13[19], 5926-5934. 2007.

Frankel AE, Smith ER, George TA, Liu JS, Lee J, Park SK, Rizzieri DA, Hogge DE. Phase I study demonstrates activity and tolerability of diphtheria toxin interleukin-3 fusion protein in patients with AML and MDS. **Blood** 110[11], 273A. 2007.

Frankel AE, Gillet D. Hormono- and immunotoxins for destroying cancer cells. **Biofutur** [276], 31-34. 2007.

Kuo SR, Willingham MC, Bour SH, Andreas EA, Park SK, Jackson C, Duesbery NS, Leppla SH, Tang WJ, Frankel AE. Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage. **Microbial Pathogenesis** . 2007.

Singh R, Browning JL, bi-Habib R, Wong K, Williams SA, Merchant R, Denmeade SR, Buckley TJ, Frankel AE. Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. **Anti-Cancer Drugs** 18[7], 809-816. 2007.

Su Y, Ortiz J, Liu S, Bugge TH, Singh R, Leppla SH, Frankel AE. Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice. **Cancer Research** 67[7], 3329-3336. 2007.

Su Y, Vanderlaag K, Ireland C, Ortiz J, Grage H, Safe S, Frankel AE. 1,1-Bis(3'-indolyl)-1-(p-biphenyl)methane inhibits basal-like breast cancer growth in athymic nude mice. **Breast Cancer Res** 9[4], R56. 2007.

Suh DY, Frankel AE. Advances in AML immunotherapy: The case for T-bodies. **Leukemia Research** 31[2], 127-128. 2007.

Watson LE, Kuo SR, Katki K, Dang T, Park SK, Dostal DE, Tang WJ, Leppla SH, Frankel AE. Anthrax toxins induce shock in rats by depressed cardiac ventricular function. **PLoS.ONE**. 2, e466. 2007.

Watson LE, Mock J, Lal H, Lu G, Bourdeau RW, Tang WJ, Leppla SH, Dostal DE, Frankel AE. Lethal and edema toxins of anthrax induce distinct hemodynamic dysfunction. **Front Biosci**. 12, 4670-4675. 2007.

Abi-Habib RJ, Singh R, Liu S, Bugge TH, Leppla SH, Frankel AE. A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types. **Mol.Cancer Ther.** 5[10], 2556-2562. 2006.

Abi-Habib RJ, Singh R, Leppla SH, Greene JJ, Ding Y, Berghuis B, Duesbery NS, Frankel AE. Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice. **Clinical Cancer Research** 12[24], 7437-7443. 2006.

Cheng HJ, Zhang CX, Masutani S, Cross M, Callahan MF, Frankel AE, Cheng CP. Beta(1)-adrenergic cAMP signaling is uncoupled after acute treatment of anthrax lethal toxin in cardiomyocytes in normal rats. **Journal of the American College of Cardiology** 47[4], 89A-90A. 2006.

Frankel AE, Weir MA, Hall PD, Hogge DE, Rizzieri DA. Diphtheria toxin-interleukin 3 fusion protein therapy of patients with elderly or relapsed/refractory acute myeloid leukemia (AML). **Journal of Clinical Oncology** 24[18], 354S. 2006.

Frankel AE, Surendranathan A, Black JH, White A, Ganjoo K, Cripe LD. Phase II clinical studies of denileukin diftiox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. **Cancer** 106[10], 2158-2164. 2006.

Hall PD, Sinha D, Frankel AE. Fresh frozen plasma and platelet concentrates may increase plasma anti-diphtheria toxin IgG concentrations: Implications for diphtheria fusion protein therapy. **Cancer Immunology, Immunotherapy** 55[8], 928-932. 2006.

Hogge DE, Yalcintepe L, Wong SH, Gerhard B, Frankel AE. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. **Clinical Cancer Research** 12[4], 1284-1291. 2006.

O'Toole PS, Thorburn J, Redzik J, Hansen K, Frankel AE, Thorburn A. Autophagy protects glioma cells against EGFR-targeted anti-cancer therapy. **Autophagy** 2[4], 362. 2006.

Thorburn A, Frankel AE. Apoptosis and anthracycline cardiotoxicity. **Mol.Cancer Ther.** 5[2], 197-199. 2006.

Yalcintepe L, Frankel AE, Hogge DE. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. **Blood** 108[10], 3530-3537. 2006.

Abi-Habib RJ, Urieto JO, Liu S, Leppla SH, Duesbery NS, Frankel AE. BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. **Mol.Cancer Ther.** 4[9], 1303-1310. 2005.

Cohen KA, Liu TF, Cline JM, Wagner JD, Hall PD, Frankel AE. Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. **Cancer Immunology, Immunotherapy** 54[8], 799-806. 2005.

Frankel AE. New anti-T cell immunotoxins for the clinic. **Leukemia Research** 29[3], 249-251. 2005.

Frankel AE, bi-Habib RJ, Urieto JO, Liu S, Leppla SH, van de Woude GF, Duesbery NS. Anthrax tumor toxin (LeTx) selectively kills B-RAF mutant melanomas. **Journal of Clinical Oncology** 23[16], 718S. 2005.

Frankel AE, Kreitman RJ. CLL immunotoxins. **Leukemia Research** 29[9], 985-986. 2005.

Hogge DE, Wong SH, Yalcintepe L, Frankel AE. The use of mouse models of normal and malignant hematopoiesis to design strategies for selective purging of primitive acute myeloid leukemia (AML) progenitors. **Biology of Blood and Marrow Transplantation** 11[2], 60. 2005.

Liu TF, Hall PD, Cohen KA, Willingham MC, Cai J, Thorburn A, Frankel AE. Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. **Clinical Cancer Research** 11[1], 329-334. 2005.

Masutani S, Cheng HJ, Callahan MF, Groban L, Smith TL, Frankel AE, Cheng CP. Chronic anthrax-lethal-toxin-induced progressive cardiac depression in mice: Effects on left ventricle and myocyte contraction, relaxation and [Ca²⁺]_i transient. **Circulation** 112[17], U332. 2005.

Testa U, Riccioni R, Biffoni M, Diverio D, Lo-Coco F, Foa R, Peschle C, Frankel AE. Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression. **Blood** 106[7], 2527-2529. 2005.

Wong L, Suh DY, Frankel AE. Toxin conjugate therapy of cancer. **Seminars in Oncology** 32[6], 591-595. 2005.

Abi-Habib RJ, Liu S, Bugge TH, Leppla SH, Frankel AE. A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts. **Blood** 104[7], 2143-2148. 2004.

Cohen KA, Liu TF, Cline JM, Wagner JD, Hall PD, Frankel AE. Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys. **Leukemia and Lymphoma** 45[8], 1647-1656. 2004.

Frankel AE, Gill PS. VEGF and myeloid leukemias. **Leukemia Research** 28[7], 675-677. 2004.

Frankel AE. Reducing the immune response to immunotoxin. **Clinical Cancer Research** 10[1 Pt 1], 13-15. 2004.

Frankel AE, Liu TF, Thorburn AM, Tatter SB, Willingham MC. Recombinant toxin DAB(389)EGF produces regressions of human glioma xenografts in nude. **Journal of Clinical Oncology** 22[14], 220S. 2004.

Hogge DE, Feuring-Buske M, Gerhard B, Frankel AE. The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia. **Leukemia Research** 28[11], 1221-1226. 2004.

Jedema I, Barge RM, Frankel AE, Willemze R, Falkenburg JH. Acute myeloid leukemia cells in G0 phase of the cell cycle that are unresponsive to conventional chemotherapy are sensitive to treatment with granulocyte-macrophage colony-stimulating factor/diphtheria toxin fusion proteins. **Experimental Hematology** 32[2], 188-194. 2004.

Kuriakose P, Turturro F, Berdeja JG, Kerr R, Surendranathan A, Black J, Frankel AE. A phase II study of denileukin diftitox (ONTAK(R)) in patients with fludarabine refractory B-cell chronic lymphocytic leukemia. **Blood** 104[11], 289B. 2004.

Liu TF, Urieto JO, Moore JE, Miller MS, Lowe AC, Thorburn A, Frankel AE. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. **Experimental Hematology** 32[3], 277-281. 2004.

Thorburn A, Thorburn J, Frankel AE. Induction of apoptosis by tumor cell-targeted toxins. **Apoptosis** 9[1], 19-25. 2004.

Urieto JO, Liu T, Black JH, Cohen KA, Hall PD, Willingham MC, Pennell LK, Hogge DE, Kreitman RJ, Frankel AE. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. **Protein Expression and Purification** 33[1], 123-133. 2004.

Westcott MM, Abi-Habib RJ, Cohen KA, Willingham MC, Liu S, Bugge TH, Leppla SH, Frankel AE. Diphtheria toxin-murine granulocyte-macrophage colony-stimulating factor-induced hepatotoxicity is mediated by Kupffer cells. **Mol.Cancer Ther.** 3[12], 1681-1689. 2004.

Wong SH, Frankel AE, Hogge DE. Variant forms of human interleukin-3 (IL-3) linked to truncated diphtheria toxin (DT388), have enhanced cytotoxicity against acute myeloid leukemia (AML) progenitors. **Blood** 104[11], 498A. 2004.

Black JH, McCubrey JA, Willingham MC, Ramage J, Hogge DE, Frankel AE. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice. **Leukemia** 17[1], 155-159. 2003.

Cohen KA, Liu T, Bissonette R, Puri RK, Frankel AE. DAB389EGF fusion protein therapy of refractory glioblastoma multiforme. **Current pharmaceutical biotechnology** 4[1], 39-49. 2003.

Frankel AE, Fleming DR, Powell BL, Gartenhaus R. DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia. **Expert.Opin.Biol.Ther.** 3[1], 179-186. 2003.

Frankel AE, Neville DM, Bugge TA, Kreitman RJ, Leppla SH. Immunotoxin therapy of hematologic malignancies. **Seminars in Oncology** 30[4], 545-557. 2003.

Frankel AE, Cohen KA, Hogge DE, Hall PD, Kreitman RJ. The AML recombinant toxin, DT(388)IL3, consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), shows safety at therapeutically active doses in cynomolgus monkeys. **Blood** 102[11], 386A. 2003.

Frankel AE, Fleming DR, Hall PD, Powell BL, Black JH, Leftwich C, Gartenhaus R. A phase II study of DT fusion protein denileukin diftotox in patients with fludarabine-refractory chronic lymphocytic leukemia. **Clinical Cancer Research** 9[10 Pt 1], 3555-3561. 2003.

Frankel AE, Koo HM, Leppla SH, Duesbery NS, Vande Woude GF. Novel protein targeted therapy of metastatic melanoma. **Current Pharmaceutical Design** 9[25], 2060-2066. 2003.

Liu TF, Tatter SB, Willingham MC, Frankel AE. Comparative study of growth factor receptor expression on human high grade gliomas and glioma cell lines. **Clinical Cancer Research** 9[16], 6127S. 2003.

Liu TF, Tatter SB, Willingham MC, Yang M, Hu JJ, Frankel AE. Growth factor receptor expression varies among high-grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. **Mol.Cancer Ther.** 2[8], 783-787. 2003.

Liu TF, Willingham MC, Tatter SB, Cohen KA, Lowe AC, Thorburn A, Frankel AE. Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells. **Bioconjugate Chemistry** 14[6], 1107-1114. 2003.

Liu TF, Cohen KA, Willingham MC, Tatter SB, Puri RK, Frankel AE. Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell culture. **Journal of Neuro-Oncology** 65[1], 77-85. 2003.

Liu TF, Cohen KA, Ramage JG, Willingham MC, Thorburn AM, Frankel AE. A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells. **Cancer Research** 63[8], 1834-1837. 2003.

Mishra G, Liu TF, Frankel AE. Recombinant toxin DAB389EGF is cytotoxic to human pancreatic cancer cells. **Expert.Opin.Biol.Ther.** 3[7], 1173-1180. 2003.

Ramage JG, Vallera DA, Black JH, Aplan PD, Kees UR, Frankel AE. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells. **Leukemia Research** 27[1], 79-84. 2003.

Riedlinger G, Kridel S, Al-Housseini AM, Brow JM, Bugge TH, Leppla SH, Duesbery N, Vande Woude G, Frankel AE. Metastatic melanoma and matrix metalloproteinases. **Drugs of the Future** 28[9], 1-8. 2003.

Thorburn J, Frankel AE, Thorburn A. Apoptosis by leukemia cell-targeted diphtheria toxin occurs via receptor-independent activation of Fas-associated death domain protein. **Clinical Cancer Research** 9[2], 861-865. 2003.

Thorburn J, Frankel AE, Thorburn A. Apoptosis by leukemia cell-targeted diphtheria toxin occurs via receptor-independent activation of Fas-associated death domain protein. **Clinical Cancer Research** 9[2], 861-865. 2003.

Feuring-Buske M, Frankel AE, Alexander RL, Gerhard B, Hogge DE. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. **Cancer Research** 62[6], 1730-1736. 2002.

Frankel AE, Powell BL, Lilly MB. Diphtheria toxin conjugate therapy of cancer. **Cancer Chemotherapy and Biological Response Modifiers** 20, 301-313. 2002.

Frankel AE, Powell BL, Hall PD, Case LD, Kreitman RJ. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. **Clinical Cancer Research** 8[5], 1004-1013. 2002.

Frankel AE, Beran M, Hogge DE, Powell BL, Thorburn A, Chen YQ, Vallera DA. Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein. **Experimental Hematology** 30[11], 1316-1323. 2002.

Frankel AE. Receptor upregulation enhances cell surface receptor targeted therapies. **Leukemia Research** 26[12], 1069-1071. 2002.

Frankel AE. Increased sophistication of immunotoxins. **Clinical Cancer Research** 8[4], 942-944. 2002.

Frankel AE. New HER2-directed therapies for breast cancer. Commentary re: C. I. Spiridon et al., Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity. *Clin. Cancer Res.*, 8: 1720-1730, 2002. **Clinical Cancer Research** 8[6], 1699-1701. 2002.

Frankel AE, Bugge TH, Liu S, Vallera DA, Leppla SH. Peptide toxins directed at the matrix dissolution systems of cancer cells. **Protein Pept.Lett.** 9[1], 1-14. 2002.

Frankel AE, Rossi P, Kuzel TM, Foss F. Diphtheria fusion protein therapy of chemoresistant malignancies. **Current Cancer Drug Targets** 2[1], 19-36. 2002.

Frankel AE, Powell BL, Duesbery NS, Vande Woude GF, Leppla SH. Anthrax fusion protein therapy of cancer. **Current protein & peptide science** 3[4], 399-407. 2002.

Frankel AE, Bugge TH, Liu SH, Vallera DA, Leppla SH. Peptide toxins directed at the matrix dissolution systems of cancer cells. **Protein and Peptide Letters** 9[1], 1-14. 2002.

Frankel AE. Receptor upregulation enhances cell surface receptor targeted therapies. **Leukemia Research** 26[12], 1069-1071. 2002.

Frankel AE, Powell BL, Hall PD, Case LD, Kreitman RJ. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT(388)GMCSF) for refractory or relapsed acute myeloid leukemia. **Clinical Cancer Research** 8[5], 1004-1013. 2002.

- Hall PD, Razzouk BI, Willoughby TE, McLean TW, Frankel AE. The majority of children and adolescents with acute myeloid leukemia have detectable anti-DT388-GMCSF IgG concentrations, but at concentrations that should not preclude in vivo activity. **Journal of Pediatric Hematology/Oncology** 24[7], 521-526. 2002.
- Hall PD, Moors M, Cao DS, Frankel AE. Improving the therapeutic index of DT388-GMCSF, a fusion toxin for the treatment of acute myeloid leukemia (AML). **Blood** 100[11], 225B-226B. 2002.
- Hall PD, Frankel AE. Reducing anti-DT IgG concentrations to improve the efficacy of a diphtheria fusion protein. **Pharmacotherapy** 22[10], 1355-1356. 2002.
- Roboz GJ, Knovich MA, Bayer RL, Schuster MW, Seiter K, Powell BL, Woodruff RD, Silver RT, Frankel AE, Feldman EJ. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. **Leukemia and Lymphoma** 43[10], 1951-1955. 2002.
- Roboz GJ, Knovich MA, Bayer RL, Schuster MW, Seiter K, Powell BL, Woodruff RD, Silver RT, Frankel AE, Feldman EJ. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. **Leukemia & Lymphoma** 43[10], 1951-1955. 2002.
- Thomas PB, Delatte SJ, Sutphin A, Frankel AE, Tagge EP. Effective targeted cytotoxicity of neuroblastoma cells. **Journal of Pediatric Surgery** 37[3], 539-544. 2002.
- Alexander RL, Ramage J, Kucera GL, Caligiuri MA, Frankel AE. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. **Leukemia Research** 25[10], 875-881. 2001.
- Frankel AE, Baer MR, Hogge DE, Stuart RK. Immunotherapy of acute myeloid leukemia. **Current pharmaceutical biotechnology** 2[3], 209-215. 2001.
- Frankel AE, Powell BL, Vallera DA, Neville DM, Jr. Chimeric fusion proteins--diphtheria toxin-based. **Current opinion in investigational drugs (London, England : 2000)** 2[9], 1294-1301. 2001.
- Frankel AE, Schuster MW, Jurcic JG. Novel therapeutics for chemotherapy-resistant acute myeloid leukaemia. **BioDrugs** 15[1], 55-71. 2001.
- Frankel AE, Powell BL, Hall PD, Mone AP, Molnar I, Kreitman RJ. Phase I trial of a novel diphtheria toxin/GM-CSF fusion protein in refractory or relapsed acute myeloid leukemia (AML). **Blood** 98[11], 722A. 2001.
- Frankel AE, Patrick CL, Powell BL. Phase II trial of the diphtheria fusion protein ONTAK in patients with fludarabine refractory chronic lymphocytic leukemia (CLL). **Blood** 98[11], 289B. 2001.
- Frankel AE, Black JH, Ramage JG, Miller MS, Hogge DE, McCubrey J, Willingham MC. Diphtheria toxin-interleukin 3 fusion protein (DT388IL3) prolongs survival of leukemic SCID mice. **Blood** 98[11], 328A. 2001.
- Hall PD, Virella G, Willoughby T, Atchley DH, Kreitman RJ, Frankel AE. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia. **Clinical Immunology** 100[2], 191-197. 2001.

- Hall PD, Razzouk BI, McLean T, Willoughby TE, Frankel AE. The majority of children and adolescents with acute myeloid leukemia (AML) are candidates for diphtheria fusion toxin therapy. **Blood** **98**[11], 213B. 2001.
- Kiser M, McCubrey JA, Steelman LS, Shelton JG, Ramage J, Alexander RL, Kucera GL, Pettenati M, Willingham MC, Miller MS, Frankel AE. Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice. **Leukemia** **15**[5], 814-818. 2001.
- Lilly MB, Zemskova M, Frankel AE, Salo J, Kraft AS. Distinct domains of the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit mediate activation of Jak/Stat signaling and differentiation. **Blood** **97**[6], 1662-1670. 2001.
- Mitchell JW, Nuchniyom B, Thorburn J, Frankel AE, Thorburn A. DT-GM, a novel fusion protein for the treatment of AML, induces apoptosis through the extrinsic pathway. **Blood** **98**[11], 181B. 2001.
- Olsen E, Duvic M, Frankel AE, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. **Journal of Clinical Oncology** **19**[2], 376-388. 2001.
- Senchenkov A, Han TY, Wang H, Frankel AE, Kottke TJ, Kaufmann SH, Cabot MC. Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT(388)-granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diphtheria toxin fused to human GM-CSF. **Blood** **98**[6], 1927-1934. 2001.
- Alexander RL, Ramage J, Klein B, Kucera GL, Caligiuri MA, Bloomfield CD, Frankel AE. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. **Blood** **96**[11], 304A. 2000.
- Alexander RL, Kucera GL, Klein B, Frankel AE. In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein. **Bioconjugate Chemistry** **11**[4], 564-568. 2000.
- Feuring-Buske M, Frankel AE, Gerhard B, Hogge DE. A diphtheria toxin-interleukin-3 fusion protein is cytotoxic to acute myeloid leukemia (AML) stem cells but spares normal progenitors. **Blood** **96**[11], 118A. 2000.
- Feuring-Buske M, Frankel AE, Gerhard B, Hogge D. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells. **Experimental Hematology** **28**[12], 1390-1400. 2000.
- Feuring-Buske M, Frankel AE, Gerhard B, Hogge DE. Selective cytotoxicity of diphtheria toxin-interleukin 3 fusion protein for acute myeloid leukemia (AML) stem cells. **Experimental Hematology** **28**[7], 81. 2000.
- Frankel AE, Kreitman RJ, Sausville EA. Targeted toxins. **Clinical Cancer Research** **6**[2], 326-334. 2000.
- Frankel AE, McCubrey JA, Miller MS, Delatte S, Ramage J, Kiser M, Kucera GL, Alexander RL, Beran M, Tagge EP, Kreitman RJ, Hogge DE. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. **Leukemia** **14**[4], 576-585. 2000.

Frankel AE, Ramage J, Kiser M, Alexander R, Kucera G, Miller MS. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. **Protein Eng** 13[8], 575-581. 2000.

Frankel AE, McCubrey JA, Miller MS, Delatte S, Ramage J, Kiser M, Kucera GL, Alexander RL, Beran M, Tagge EP, Kreitman RJ, Hogge DE. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. **Leukemia** 14[4], 576-585. 2000.

Frankel AE, Sievers EL, Scheinberg DA. Cell surface receptor-targeted therapy of acute myeloid leukemia: a review. **Cancer Biotherapy & Radiopharmaceuticals** 15[5], 459-476. 2000.

Lilly MB, Frankel AE, Salo J, Kraft AS. Distinct domains of the human GM-CSF receptor alpha subunit mediate activation of Jak/Stat signaling and differentiation. **Blood** 96[11], 572A-+. 2000.

McCubrey JA, Shelton JG, Steelman LS, Pearce ML, Blalock WL, Cooke HJ, Kisser M, Frankel AE. Enhanced ability of DT-IL3 to induce apoptosis in oncogene transformed human hematopoietic cells. **Blood** 96[11], 97A. 2000.

Molnar I, Hall PD, Willoghby T, Mone A, Kreitman RJ, Frankel AE. Pharmacologic and immunologic studies of a diphtheria fusion protein in patients with relapsed or refractory AML. **Blood** 96[11], 122A-123A. 2000.

Mone AP, Howard DE, Molnar I, Kreitman RJ, Frankel AE. Resistant acute myeloid leukemia responds to a novel diphtheria toxin/GM-CSF fusion protein: Summary of an ongoing phase I trial. **Blood** 96[11], 117A. 2000.

Feuring-Buske M, Frankel AE, Gerhard B, Hogge DE. Cytotoxicity of diphtheria toxin-granulocyte macrophage colony stimulating factor (DT-GMCSF) fusion protein for acute myelogenous leukemia (AML) stem cells. **Blood** 94[10], 79A. 1999.

Frankel AE, Hall PD, Kreitman RJ. Steroid prophylaxis prevents systemic inflammatory response syndrome (SIRS) in AML patients treated with diphtheria fusion protein. **Blood** 94[10], 229B. 1999.

Frankel AE, Ramage J, Latimer A, Feely T, Delatte S, Hall P, Tagge E, Kreitman R, Willingham M. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials. **Protein Expression and Purification** 16[1], 190-201. 1999.

Hall PD, Virella G, Beckham W, Frankel AE. The majority of adult patients with acute myeloid leukemia (AML) have low to undetectable concentrations of antibodies against DTGM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte macrophage colony stimulating factor (GM). **Blood** 94[10], 64A. 1999.

Hall PD, Willingham MC, Kreitman RJ, Frankel AE. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia. **Leukemia** 13[4], 629-633. 1999.

Hotchkiss CE, Hall PD, Cline JM, Willingham MC, Kreitman RJ, Gardin J, Latimer A, Ramage J, Feely T, Delatte S, Tagge EP, Frankel AE. Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor, in cynomolgus monkeys. **Toxicology and Applied Pharmacology** 158[2], 152-160. 1999.

- Kim CN, Bhalla K, Kreitman RJ, Willingham MC, Hall P, Tagge EP, Jia T, Frankel AE. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells. **Leukemia Research** 23[6], 527-538. 1999.
- Byeon MK, Frankel AE, Papas TS, Henderson KW, Schweinfest CW. Human DRA functions as a sulfate transporter in Sf9 insect cells. **Protein Expression and Purification** 12[1], 67-74. 1998.
- Duvic M, Cather J, Maize J, Frankel AE. DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. **American Journal of Hematology** 58[1], 87-90. 1998.
- Frankel AE, Lilly M, Kreitman R, Hogge D, Beran M, Freedman MH, Emanuel PD, McLain C, Hall P, Tagge E, Berger M, Eaves C. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. **Blood** 92[11], 4279-4286. 1998.
- Frankel AE, Lilly M, Kreitman R, Hogge D, Beran M, Freedman MH, Emanuel PD, McLain C, Hall P, Tagge E, Berger M, Eaves C. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. **Blood** 92[11], 4279-4286. 1998.
- Frankel AE, Hall PD, McLain C, Safa AR, Tagge EP, Kreitman RJ. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF. **Bioconjugate Chemistry** 9[4], 490-496. 1998.
- Frankel AE, Wagner H, Cooper M, et al. Clinical applications of immunotoxins. **Current Topics in Microbiology and Immunology** 234[July]. 1998.
- Hall PD, Kreitman RJ, Willingham MC, Frankel AE. Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL/6 mice. **Toxicology and Applied Pharmacology** 150[1], 91-97. 1998.
- Hall PD, Kreitman RJ, Willingham MC, Frankel AE. DT388-GM-CSF, a fusion toxin targeting the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor, improves survival of SCID mice bearing human acute myeloid leukemia (AML) blasts over ARA-C. **Blood** 92[10], 615A. 1998.
- Hogge DE, Willman CL, Kreitman RJ, Berger M, Hall PD, Kopecky KJ, McLain C, Tagge EP, Eaves CJ, Frankel AE. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein. **Blood** 92[2], 589-595. 1998.
- Burbage C, Tagge EP, Harris B, Hall P, Fu T, Willingham MC, Frankel AE. Ricin fusion toxin targeted to the human granulocyte-macrophage colony stimulating factor receptor is selectively toxic to acute myeloid leukemia cells. **Leukemia Research** 21[7], 681-690. 1997.
- Frankel AE, Fu T, Burbage C, Chandler J, Willingham MC, Tagge EP. IL2 fused to lectin-deficient ricin is toxic to human leukemia cells expressing the IL2 receptor. **Leukemia** 11[1], 22-30. 1997.
- Frankel AE, Hall PD, Safa AR, Bhalla K, Tagge EP, Kreitman RJ. Targeted toxins are cell-specific modulators of drug resistance in AML. **Blood** 90[10], 807. 1997.

- Frankel AE, Hall PD, Burbage C, Vesely J, Willingham M, Bhalla K, Kreitman RJ. Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein. **Blood** 90[9], 3654-3661. 1997.
- Frankel AE, Laver JH, Willingham MC, Burns LJ, Kersey JH, Vallera DA. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. **Leukemia and Lymphoma** 26[3-4], 287-298. 1997.
- Frankel AE, Fu T, Burbage C, Tagge E, Harris B, Vesely J, Willingham MC. Lectin-deficient ricin toxin intoxicates cells bearing the D-mannose receptor. **Carbohydrate Research** 300[3], 251-258. 1997.
- Hall PD, Kreitman RJ, Willingham MC, Frankel AE. Pharmacology and toxicology of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin linked to granulocyte-macrophage colony stimulating factor (GM-CSF). **Blood** 90[10], 3828. 1997.
- Tagge E, Harris B, Burbage C, Hall P, Vesely J, Willingham M, Frankel AE. Routing of green fluorescent protein-ricin to the Golgi correlates with cell sensitivity to toxins. **Bioconjugate Chemistry** 8, 743-750. 1997.
- Brothers TE, Boggs J, Goldsmith C, Frankel AE, Willingham MC. Fibrin matrix for local delivery of a mitotoxin to inhibit vascular smooth muscle cell proliferation. **FASEB Journal** 10[3], 3582. 1996.
- Byeon M, Frankel AE, Westerman MA, Green JE, Papas TS, Henderson KW, Schweinfest CW. Human DRA encodes an intestine-specific sulfate transporter. **Molecular Biology of the Cell** 7, 1491. 1996.
- Chandler JC, Frankel AE, Tagge EP. Genetic engineering of immunotoxins. **Seminars in Pediatric Surgery** 5[3], 206-211. 1996.
- Day PJ, Ernst SR, Frankel AE, Monzingo AF, Pascal JM, Molina-Svinth MC, Robertus JD. Structure and activity of an active site substitution of ricin A chain. **Biochemistry** 35[34], 11098-11103. 1996.
- Frankel AE, FitzGerald D, Siegall C, Press OW. Advances in immunotoxin biology and therapy: a summary of the Fourth International Symposium on Immunotoxins. **Cancer Research** 56[4], 926-932. 1996.
- Frankel AE, Burbage C, Fu T, Tagge E, Chandler J, Willingham M. Characterization of a ricin fusion toxin targeted to the interleukin-2 receptor. **Protein Eng** 9[10], 913-919. 1996.
- Frankel AE, Fu T, Burbage C, Harris B, Willingham M, Perentesis J, Tagge E. GM-CSF-ricin fusion toxin therapy of myeloid malignancies. **Blood** 88[10], 1431. 1996.
- Frankel AE, Burbage C, Fu T, Tagge E, Chandler J, Willingham MC. Ricin toxin contains at least three galactose-binding sites located in B chain subdomains 1 alpha, 1 beta, and 2 gamma. **Biochemistry** 35[47], 14749-14756. 1996.
- Frankel AE, Tagge E, Chandler J, Burbage C, Hancock G, Vesely J, Willingham M. Characterization of single site ricin toxin B chain mutants. **Bioconjugate Chemistry** 7[1], 30-37. 1996.
- Frankel AE, Tagge E, Chandler J, Burbage C, Willingham M. Double-site ricin B chain mutants retain galactose binding. **Protein Eng** 9[4], 371-379. 1996.

Fu T, Burbage C, Tagge E, Chandler J, Willingham M, Frankel AE. Double-lectin site ricin B chain mutants expressed in insect cells have residual galactose binding: evidence for more than two lectin sites on the ricin toxin B chain. **Bioconjugate Chemistry** 7[6], 651-658. 1996.

Fu T, Burbage C, Tagge EP, Brothers T, Willingham MC, Frankel AE. Ricin toxin contains three lectin sites which contribute to its in vivo toxicity. **International Journal of Immunopharmacology** 18[12], 685-692. 1996.

Re GG, Waters C, Poisson L, Willingham MC, Sugamura K, Frankel AE. Interleukin 2 (IL-2) receptor expression and sensitivity to diphtheria fusion toxin DAB389IL-2 in cultured hematopoietic cells. **Cancer Research** 56[11], 2590-2595. 1996.

Tagge E, Chandler J, Tang BL, Hong W, Willingham MC, Frankel AE. Cytotoxicity of KDEL-terminated ricin toxins correlates with distribution of the KDEL receptor in the Golgi. **Journal of Histochemistry and Cytochemistry** 44[2], 159-165. 1996.

Tagge EP, Tagge DU, Chandler JC, Pitre BR, Haddad G, Frankel AE, Willingham MC, Garvin AJ, Papas TS. Molecular biology and the pediatric surgeon: definitions and basic methodology. **Seminars in Pediatric Surgery** 5[3], 139-148. 1996.

Tagge EP, Chandler J, Harris B, Czako M, Marton L, Willingham MC, Burbage C, Afrin L, Frankel AE. Preproricin expressed in *Nicotiana tabacum* cells in vitro is fully processed and biologically active. **Protein Expression and Purification** 8[1], 109-118. 1996.

Vallera DA, Burns LJ, Frankel AE, Sicheneder AR, Gunther R, Gajl-Peczalska K, Pennell CA, Kersey JH. Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies. **Journal of Immunological Methods** 197[1-2], 69-83. 1996.

Brothers TE, Robison JG, Elliott BM, Boggs JM, Frankel AE, Willingham MC. Upregulation of b-FGF receptor expression after carotid bypass. **Journal of Surgical Research** 58[1], 28-32. 1995.

Frankel AE, Tagge E, Chandler J, Burbage C, Hancock G, Vesely J, Willingham M. IL2-ricin fusion toxin is selectively cytotoxic in vitro to IL2 receptor-bearing tumor cells. **Bioconjugate Chemistry** 6[6], 666-672. 1995.

Frankel AE, Tagge EP, Willingham MC. Clinical trials of targeted toxins. **Seminars in Cancer Biology** 6[5], 307-317. 1995.

Tagge E, Chandler J, Tagge D, Burbage C, Hancock G, Vesely J, Willingham M, Frankel AE. A selective cytotoxicity of a genetically engineered IL2-ricin fusion toxin to tumor cells bearing the IL2 receptor. **Surgical Forum** 46, 672-675. 1995.

Tonevitsky A, Toptygin A, Agapov I, Rakhmanova V, Shamshiev A, Alekseev I, Pfueller U, Frankel AE. Production of biologically active recombinant ricin B chain. **Molekuliarnaia Biologiya** 29, 398-406. 1995.

Willingham MC, Brothers TE, Tagge DU, Frankel AE. Endothelial Apoptosis in Immunotoxin-Induced Vascular Leak Syndrome - An In-Vitro Model. **Laboratory Investigation** 72[1], A36. 1995.

Afrin LB, Gulick H, Vesely J, Willingham M, Frankel AE. Expression of oligohistidine-tagged ricin B chain in *Spodoptera frugiperda*. **Bioconjugate Chemistry** 5[6], 539-546. 1994.

- Frankel AE, Roberts H, Gulick H, Afrin L, Vesely J, Willingham M. Expression of ricin B chain in Spodoptera frugiperda. **Biochemical Journal** 303 (Pt 3), 787-794. 1994.
- Sehnke PC, Pedrosa L, Paul AL, Frankel AE, Ferl RJ. Expression of active, processed ricin in transgenic tobacco. **Journal of Biological Chemistry** 269[36], 22473-22476. 1994.
- Tonevitsky A, Toptygin A, Agapov I, Pfueller U, Frankel AE. Renaturated ricin toxin B chain made in Escherichia coli is soluble, stable, and biologically active. **Biochemistry and Molecular Biology International** 32[6], 1139-1146. 1994.
- Tonevitsky A, Agapov I, Bushueva T, Toptygin A, Shamshiev A, Frankel AE, Debabov V. The effect of glycosylation on the structure, stability and biological activity of ricin toxin B-chain. **Doklady Akademii Nauk** 336, 700-703. 1994.
- Frankel AE. Immunotoxin therapy of cancer. **Oncology (Williston.Park)** 7[5], 69-78. 1993.
- Kim Y, Mlsna D, Monzingo AF, Ready MP, Frankel AE, Robertus JD. Structure of a ricin mutant showing rescue of activity by a noncatalytic residue. **Biochemistry** 31[12], 3294-3296. 1992.
- Li BY, Frankel AE, Ramakrishnan S. High-level expression and simplified purification of recombinant ricin A chain. **Protein Expression and Purification** 3[5], 386-394. 1992.
- Olsnes S, Frankel AE. Genetically engineered toxins in perspective. **Targeted Diagnosis and Therapy** 7, 465-477. 1992.
- Hertler AA, Frankel AE. Immunotoxins in the therapy of leukemias and lymphomas. **Cancer Investigation** 9[2], 211-219. 1991.
- LeMaistre CF, Rosen S, Frankel AE, Kornfeld S, Saria E, Meneghetti C, Drajesk J, Fishwild D, Scannon P, Byers V. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. **Blood** 78[5], 1173-1182. 1991.
- Oelmann TN, Frankel AE. Advances in immunotoxins. **FASEB Journal** 5[10], 2334-2337. 1991.
- Frankel AE, Welsh P, Richardson J, Robertus JD. Role of arginine 180 and glutamic acid 177 of ricin toxin A chain in enzymatic inactivation of ribosomes. **Mol.Cell Biol.** 10[12], 6257-6263. 1990.
- Frankel AE, Schlossman D, Welsh P, Hertler A, Withers D, Johnston S. Selection and characterization of ricin toxin A-chain mutations in Saccharomyces cerevisiae. **Mol.Cell Biol.** 9[2], 415-420. 1989.
- Gould BJ, Borowitz MJ, Groves ES, Carter PW, Anthony D, Weiner LM, Frankel AE. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. **Journal of the National Cancer Institute** 81[10], 775-781. 1989.
- Hertler AA, Schlossman DM, Borowitz MJ, Poplack DG, Frankel AE. An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys. **Cancer Immunology, Immunotherapy** 28[1], 59-66. 1989.
- Hertler AA, Schlossman DM, Borowitz MJ, Blythman HE, Casellas P, Frankel AE. An anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin. **International Journal of Cancer** 43[2], 215-219. 1989.

- Hertler AA, Frankel AE. Immunotoxins: a clinical review of their use in the treatment of malignancies. **Journal of Clinical Oncology** 7[12], 1932-1942. 1989.
- Ring DB, Kassel JA, Hsieh-Ma ST, Bjorn MJ, Tringale F, Eaton AM, Reid SA, Frankel AE, Nadji M. Distribution and physical properties of BCA200, a Mr 200,000 glycoprotein selectively associated with human breast cancer. **Cancer Research** 49[11], 3070-3080. 1989.
- Schlossman D, Withers D, Welsh P, Alexander A, Robertus J, Frankel AE. Role of glutamic acid 177 of the ricin toxin A chain in enzymatic inactivation of ribosomes. **Mol.Cell Biol.** 9[11], 5012-5021. 1989.
- Weiner LM, O'Dwyer J, Kitson J, Comis RL, Frankel AE, Bauer RJ, Konrad MS, Groves ES. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. **Cancer Research** 49[14], 4062-4067. 1989.
- Frankel AE, Welsh PC, Withers DI, Schlossman DM. Immunotoxin preparation and testing in vitro. **Targeted Diagnosis and Therapy** 1, 225-244. 1988.
- Hertler AA, Schlossman DM, Borowitz MJ, Laurent G, Jansen FK, Schmidt C, Frankel AE. A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. **Journal of Biological Response Modifiers** 7[1], 97-113. 1988.
- Laurent G, Frankel AE, Hertler AA, Schlossman DM, Casellas P, Jansen FK. Treatment of leukemia patients with T101 ricin A chain immunotoxins. **Cancer Treatment and Research** 37, 483-491. 1988.
- FitzGerald DJ, Bjorn MJ, Ferris RJ, Winkelhake JL, Frankel AE, Hamilton TC, Ozols RF, Willingham MC, Pastan I. Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer. **Cancer Research** 47[5], 1407-1410. 1987.
- Hertler AA, Spitler LE, Frankel AE. Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma. **Cancer Drug Delivery** 4[4], 245-253. 1987.
- Frankel AE, Houston LL, Issell BF, Fathman G. Prospects for immunotoxin therapy in cancer. **Annual Review of Medicine** 37, 125-142. 1986.
- Linsley PS, Ochs V, Horn D, Ring DB, Frankel AE. Heritable variation in expression of multiple tumor associated epitopes on a high molecular weight mucin-like antigen. **Cancer Research** 46[12 Pt 1], 6380-6386. 1986.
- Linsley PS, Ochs V, Laska S, Horn D, Ring DB, Frankel AE, Brown JP. Elevated levels of a high molecular weight antigen detected by antibody W1 in sera from breast cancer patients. **Cancer Research** 46[10], 5444-5450. 1986.
- Bjorn MJ, Ring D, Frankel AE. Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. **Cancer Research** 45[3], 1214-1221. 1985.
- Bogden AE, Frankel AE, Chong KT, Winkelhake J. Human-Tumor Xenograft Responses to Immunoconjugates in Parallel Subcutaneous (Sc) and Subrenal Capsule (Src) Assays. **Proceedings of the American Association for Cancer Research** 26[MAR], 287. 1985.
- Frankel AE. Antibody-toxin hybrids: a clinical review of their use. **Journal of Biological Response Modifiers** 4[5], 437-446. 1985.

Frankel AE, Ring DB, Tringale F, Hsieh-Ma ST. Tissue distribution of breast cancer-associated antigens defined by monoclonal antibodies. **Journal of Biological Response Modifiers** 4[3], 273-286. 1985.

McGuire WL, Ceriani RL, Schlom J, Frankel AE. Monoclonal antibodies, benign breast disease, and breast cancer. A panel discussion. **Breast Cancer Research and Treatment** 6[1], 37-47. 1985.

Pirker R, FitzGerald DJ, Hamilton TC, Ozols RF, Laird W, Frankel AE, Willingham MC, Pastan I. Characterization of immunotoxins active against ovarian cancer cell lines. **Journal of Clinical Investigation** 76[3], 1261-1267. 1985.

Winkelhake J, Frankel AE, Ring D, Bjorn M, Chong KT, Hwang K. Breast-Cancer Immunotoxins. **Federation Proceedings** 44[5], 1684. 1985.

Frankel AE, Rouse RV, Wang MC, Chu TM, Herzenberg LA. Monoclonal antibodies to a human prostate antigen. **Cancer Research** 42[9], 3714-3718. 1982.

Frankel AE, Rouse RV, Herzenberg LA. Human prostate specific and shared differentiation antigens defined by monoclonal antibodies. **Proc.Natl.Acad.Sci.U.S.A** 79[3], 903-907. 1982.

Minowada J, Minato K, Tatsumi E, Sugimoto T, Nakazawa S, Ohnuma T, Jubonishi I, Miyoshi I, Frankel AE. Differentiation as determined by multiple markers of leukemia-lymphomas. **Hematology and Blood Transfusion** 28, 348-350. 1982.

Fischinger PJ, Blevins CS, Frankel AE, Tuttle-Fuller N, Haapala DK, Nomura S, Robey WG. Biological, immunological, and molecular properties of revertants of cat cells transformed by murine sarcoma virus. **Cancer Research** 41[3], 958-965. 1981.

Frankel AE, Rubenstein MD, Wall RT. Thrombotic thrombocytopenic purpura: prolonged coma with recovery of neurologic function with intensive plasma exchange. **American Journal of Hematology** 10[4], 387-390. 1981.

Fawcett HD, Lantieri RL, Frankel AE, McDougall IR. Differentiating hepatic abscess from tumor: combined ¹¹¹In white blood cell and ^{99m}Tc liver scans. **AJR.American Journal of Roentgenology** 135[1], 53-56. 1980.

Frankel AE, Gilbert JH, Porzig KJ, Scolnick EM, Aaronson SA. Nature and distribution of feline sarcoma virus nucleotide sequences. **Journal of Virology** 30[3], 821-827. 1979.

Fischinger PJ, Frankel AE, Elder JH, Lerner RA, Ihle JN, Bolognesi DP. Biological, immunological, and biochemical evidence that HIX virus is a recombinant between Moloney leukemia virus and a murine xenotropic C type virus. **Virology** 90[2], 241-254. 1978.

Frankel AE, Gilbert JH, Fischinger PJ. Effect of helper virus on the number of murine sarcoma virus DNA copies in infected mammalian cells. **Journal of Virology** 23[3], 492-502. 1977.

Frankel AE, Fischinger PJ. Rate of divergence of cellular sequences homologous to segments of Moloney sarcoma virus. **Journal of Virology** 21[1], 153-160. 1977.

Frankel AE, Neubauer RL, Fischinger PJ. Fractionation of DNA nucleotide transcripts from Moloney sarcoma virus and isolation of sarcoma virus-specific complementary DNA. **Journal of Virology** 18[2], 481-490. 1976.

Frankel AE, Fischinger PJ. Nucleotide sequences in mouse DNA and RNA specific for Moloney sarcoma virus. **Proc.Natl.Acad.Sci.U.S.A** 73[10], 3705-3709. 1976.

Frankel AE, Haapala DK, Neubauer RL, Fischinger PJ. Elimination of Sarcoma Genome from Murine Sarcoma-Virus Transformed Cat Cells. **Science** 191[4233], 1264-1266. 1976.

Book Chapters

Frankel AE, Hall PD, Cao D, Liu TF, Moors M, Cohen KA, Thorburn AM, Kreitman RJ. GM-CSF receptor targeted therapy of human leukemia. **Cytotoxins and Immunotoxins for Cancer Therapy**. 2004. Boca Ratan, CRC Press.

Frankel AE, Kreitman RJ. Immunotoxin therapy of chronic lymphocytic leukemia. **Chronic Lymphocytic Leukemia: Molecular Genetics, Biology, Diagnosis and Management**, 299-314. 2003. Totawa, Human Press.

Frankel AE, Kreitman RJ, Pastan I, Murphy JR. Immunotoxins. **Principles of Cancer Biotherapy**, 391-433. 2003. London, Kluwer Academic Pub.

Frankel AE, Hall PD. Bacterial and plant toxins--general mode of action. **Chimeric Toxins: Mechanisms of Action and Therapeutic Applications**, 1-13. 2002. London, Taylor & Francis.

Sievers EL, Frankel AE. Treatment of acute leukemia with monoclonal antibodies, immunotoxins, and immunoconjugates. **Leukemia** 7th ed., 441-448. 2002. Philadelphia, Saunders.

Bast R, Zalutsky M, Frankel AE. Monoclonal serotherapy. **Cancer Medicine**. 1992. Philadelphia, Lea & Febiger.

Robertus J, Frankel AE. Immunotoxins. **Encyclopedia of Human Biology, Vol. 4**, 415-422. 1991. San Diego, Academic Press.

Frankel AE, Welsh P, Withers D, Schlossman D. Immunotoxin preparation and testing in vitro. **Antibody-Mediated Delivery Systems**, 225-244. 1988. New York, Marcel Dekker.

Frankel AE, Boyer C, Bast R. Immunobiology of human breast cancer. **Immunology of Malignant Diseases**, 167-224. 1987. Lancaster, MTO Press.

Frankel AE, Bjorn M, Winkelhake J. Antibody targeting of toxin polypeptides. **Protein Engineering**, 351-363. 1986. Orlando, Academic Press.

Frankel AE, Miller R. Monoclonal antibodies in cancer treatment. **Fundamentals of Cancer Chemotherapy**, 488-498. 1986. New York, McGraw-Hill.

Frankel AE, Ring D, Bjorn M, Bloch W, Laird W, Chong K, Hwang K, Winkelhake J. Breast cancer immunotoxins. **Monoclonal Antibodies and Breast Cancer**, 269-292. 1985. Boston, Martinus Nihjoff Pub.

Fischinger P, Frankel AE. Species specific actions of vertebrate oncornaviruses: origins, interactions and oncogenesis. **Neoplasms: Comparative Pathology of Growth in Animals, Plants, and Man**, 407-422. 1981. Baltimore, Williams & Wilkins.

Ledbetter J, Frankel AE, Herzenberg L. Human Leu T-cell differentiation antigens: Quantitative expression on normal lymphoid cells and cell lines. **Monoclonal Antibodies and T-cell Hybridomas**, 16-22. 1981. Amsterdam, Elsevier/North Holland.

Frankel AE, Fischinger P. Selective amplification of murine sarcoma virus proviral DNA in productively infected mammalian cells. **Advances in Comparative Leukemia Research**, 171-173. 1978. Amsterdam, Elsevier/North Holland.

Books

Frankel AE. **Genetically Engineered Toxins** . New York, Marcel Dekker, 1992

Frankel AE. **Immunotoxins**. Boston, Kluwer Academic. 1988